RTX-117
/ ReviR Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 23, 2026
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study and Food Affect (FE) study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RTX-117 in Healthy Volunteers
(ChiCTR)
- P1 | N=64 | Sponsor: Shanghai Xuhui Central Hospital; Xi Li Technology (Shenzhen) Co., Ltd
New P1 trial • Genetic Disorders
1 to 1
Of
1
Go to page
1